Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood-brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
1 in 6 People Worldwide
Neurological disease affects 1.25 billion people worldwide, and the incidence of these disorders is only increasing. Bioasis is determined to deliver effective treatments to patients suffering with these diseases.
Our Science
A Barrier to Better Health
The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. However, it also blocks otherwise effective medicine from reaching the brain. Most drugs created to treat central nervous system diseases and disorders fail because they aren't optimally designed to be delivered in sufficient quantities to the brain.
Blood-Brain Barrier
Transporting Treatment
The Bioasis xB3 platform provides researchers with a path for the delivery of treatments across the blood-brain barrier and into the brain. Our technology offers a solution to a problem that for decades has blocked development of effective treatment of neurological disorders.
Our Platform
Latest News
Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of xB3-001, the Company’s Lead Investigational Candidate to Treat Brain CancerMay. 21, 2018
Bioasis will draw on WuXi Biologics’ expertise in developing complex biologic molecules for production of xB 3 -001 to support analytical development, formulation and IND-enabling in vivo studies
Bioasis Announces Closing of First Tranche of Previously Disclosed Private PlacementMay. 17, 2018
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Bioasis Announces Private Placement and Intention to Pursue NASDAQ ListingMay. 14, 2018
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES